Reneuron (RENE.L) is a stem cell research company whose focus is on therapies targeting areas of poorly met medical need, including peripheral arterial disease, stroke, and retinal diseases. RENE is currently testing the effects of neural stem cells on spines for neuroregeneration, and is testing the use of fetal stem cells on stroke patients.
A UK company, used as a scientific comparable due to status of trials and disease state.
March 21, 2022
RegMed Investors’ (RMi) closing bell: sector highs respond to lessened resistance motivating sentiment
March 21, 2022
RegMed Investors’ (RMi) pre-open: holding onto gains or evacuate from risk
March 21, 2022
RegMed Investors’ (RMi) pre-open: holding onto gains or evacuate from risk
March 17, 2022
RegMed Investors’ (RMi) closing bell: Algorithmic tailwinds are pushing the cell and gene therapy sector upward
March 11, 2022
RegMed Investors’ (RMi) closing bell: escalated depreciation in the cell and gene therapy sector
March 10, 2022
RegMed Investors’ (RMi) closing bell: the algorithms beat me to the profit window
March 9, 2022
RegMed Investors’ (RMi) closing bell: a pocket of appreciation, how long will it last?
March 8, 2022
RegMed Investors’ (RMi) closing bell: news, earnings and oversold conditions drive sector’s risk slide
March 7, 2022
RegMed Investors’ (RMi) closing bell: the economic ramifications of disruption, selling into oversold conditions
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors